Cardiogenesis submits an IDE for its PHOENIX System Cardiogenesis Corporation india pharmacy.

Cardiogenesis submits an IDE for its PHOENIX System Cardiogenesis Corporation , today announced that it all has submitted an IDE to the Food and Drug Administration to initiate a basic safety and feasibility trial for its PHOENIX Program in sufferers with refractory angina. The PHOENIX handpiece may be the first device specifically designed to allow physician-directed cells stimulation and injections of biologic or pharmacologic brokers to pre-determined areas of myocardium. Dr india pharmacy . Guillermo Reyes, Department of Cardiovascular Medical procedures, Medical center Universitario La Princesa, Madrid, Spain commented on his preliminary scientific experience with the device. To date I’ve successfully treated eighteen patients using the PHOENIX with bone marrow derived stem cells.


Related StoriesBrain health: how will you reduce cognitive decline? An interview with Heather Snyder, Ph.D.Deaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHMEInnovation in anaesthesia: an interview with Matti Lehtonen, GE Healthcare’We are very encouraged by the results seen in the first clinical trial for CXL-1427,’ said ShiYin Foo, M.D., Ph.D., Cardioxyl's Chief Medical Officer, ‘and we are excited to have begun our next stage of clinical tests in advanced heart failure patients. Heart failure individuals have few effective options, and the pre-scientific and scientific data for CXL-1427 claim that this could be an important new therapy for individuals with ADHF.’ Nitroxyl, the chemical name for HNO, provides been studied for its potential as a treatment for heart failure.

Related Articles

Other Articles from "tomography":